Close
Help




JOURNAL

Clinical Medicine Insights: Therapeutics

Safety and Efficacy of Imidapril in the Treatment of Essential Hypertension

Submit a Paper


Clinical Medicine Insights: Therapeutics 2011:3 477-486

Review

Published on 01 Nov 2011

DOI: 10.4137/CMT.S7662


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics

Abstract

Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are one of the renin angiotensin system (RAS) inhibitors widely used for the treatment of hypertension. Recently, Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) meta-analysis showed that ACEIs had the blood pressure independent beneficial effects on coronary heart events. In this review, we summarized our current knowledge about ACEIs especially imidapril and re-evaluated ACEIs among other RAS inhibitors (RASIs) because ACEIs have wide ranges of beneficial effects in addition to the ACE inhibition which other RASIs do not have such as the up-regulation of bradykinin level, substance P level, the inhibition of matrix metalloproteinase (MMP) activity and stabilization of coronary plaque.



Downloads

PDF  (1.10 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
My publishing experience with Libertas was truly an enjoyable experience.  I really appreciate the rapid response to my questions and support that I received as an author. I would highly recommend Libertas to other authors.
Dr Wanda C Reygaert (Oakland University William, Beaumont School of Medicine, Rochester, MI, USA)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube